GO
Loading...

Enter multiple symbols separated by commas

Johnson & Johnson

More

  • Abbvie completes $21 billion buyout of Pharmacyclics Tuesday, 26 May 2015 | 11:15 AM ET

    NEW YORK— Abbvie has completed its $21 billion buyout of Pharmacyclics. The buyout adds another major revenue producer to Abbvie's portfolio, which already includes the world's top-selling drug, Humira. Pharmacyclics Inc. will become a subsidiary of Abbvie and operate from its Sunnyvale, California headquarters.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • SACRAMENTO, Calif.— The California Assembly on Friday approved one of the nation's toughest bans on plastic, exfoliating microbeads that are polluting waterways. Manufacturers already have pledged to phase out the materials, including L'Oreal, Unilever and Johnson& Johnson, and use natural alternatives such as apricot shells and cocoa beans.

  • NEW YORK— Abbvie Inc. specified the stock and cash breakdown on Thursday of its previously announced $21 billion buyout of Pharmacyclics Inc.. The drugmaker said the mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie...

  • CVS paying $10.4B in cash for drug distributor Omnicare Thursday, 21 May 2015 | 7:18 AM ET

    CVS Health will pay more than $10 billion for pharmaceutical distributor Omnicare in a deal primed to feed its fast-growing specialty drug business and tap a lucrative and growing market: care for the elderly. Omnicare's long-term care business operates in 47 states and the District of Columbia. Cincinnati- based Omnicare's core business involves...

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • 19)@ (Corrects paragraphs 2 and 3 to say J&J's $1.1 billion potential payments include equity investment of $225 million and are not in addition to the $1.1 billion). May 19 (Reuters)- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and...

  • Achillion sinks after partnering with Johnson & Johnson Wednesday, 20 May 2015 | 11:38 AM ET

    Investors started shedding Achillion shares early Wednesday, less than a day after the drugmaker announced a partnership with pharmaceutical giant Johnson& Johnson that snuffed out the prospect of a near-term acquisition. Achillion representatives said during a conference call that Johnson& Johnson will make a $225 million equity investment in their...

  • NEW YORK, May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of the experimental drug daratumumab for the blood cancer...

  • J&J: 10 new drugs by 2019, each with $1B potential Wednesday, 20 May 2015 | 9:11 AM ET
    Johnson & Johnson's Janssen Labs in La Jolla, California.

    "You're going to have some wins and some that don't turn out," J&J chief Alex Gorsky tells CNBC. "But overall we're very confident."

  • Johnson & Johnson makes what?!   Wednesday, 20 May 2015 | 8:30 AM ET
    Johnson & Johnson makes what?!

    The consumer products giant makes much more than baby powder. Some of what it sells may surprise you.

  • NEW BRUNSWICK, N.J.— Johnson& Johnson is predicting big returns from its prescription drug business, both financially and medically, as it develops treatments and strategies to intervene earlier and prevent or reduce the damage from several conditions, including Alzheimer's disease and diabetes. "We believe we will continue to deliver above-industry growth...

  • JNJ CEO: Always on the hunt for new platforms   Wednesday, 20 May 2015 | 8:12 AM ET
    JNJ CEO:  Always on the hunt for new platforms

    Alex Gorsky, Johnson & Johnson chairman & CEO, discusses the company's search for new scientific platforms and potential M&A prospects.

  • JNJ's 'balance approach' accounts for success: CEO   Wednesday, 20 May 2015 | 8:08 AM ET
    JNJ's 'balance approach' accounts for success: CEO

    Alex Gorsky, Johnson & Johnson chairman & CEO, talks about the company's plan to keep its diverse portfolio.

  • Driving innovation in pharma: JNJ CEO   Wednesday, 20 May 2015 | 8:05 AM ET
    Driving innovation in pharma: JNJ CEO

    Alex Gorsky, Johnson & Johnson chairman & CEO, discusses new drugs in the company's pipeline, promising results in oncology, and defending the company's franchise.

  • Early movers: LOW, JNJ, YHOO, HRL, NOC & more Wednesday, 20 May 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • JNJ expects 10 new drug filings by 2019   Wednesday, 20 May 2015 | 7:30 AM ET
    JNJ expects 10 new drug filings by 2019

    CNBC's Meg Tirrell has the update on JNJ's new drugs announcement, which has a $1 billion potential for each new drug.

  • May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time. Johnson& Johnson will also invest $225 million in Achillion in return for about 18.4 million unregistered shares at $12.25 per share.

  • Achillion partners with J&J to develop hep C drugs Tuesday, 19 May 2015 | 4:29 PM ET

    May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market one or more of its hepatitis C drugs. Achillion will be eligible for milestone payments of up to $1.1 billion related to the development, regulatory approval and sales of the drugs. Johnson& Johnson will also invest $225 million in Achillion in return for...

  • May 19- The U.S. Food and Drug Administration approved a longer-acting version of Johnson& Johnson's schizophrenia treatment, developed by the company's Janssen Pharmaceuticals unit. The FDA approved the drug, Invega Trinza, to be administered just four times a year, the longest dosing interval available for the treatment of the neurological disorder,...